The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
 
Nazli Dizman
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Agensys (Inst); AstraZeneca; Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Lilly; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis
 
Harris S. Soifer
Employment - bioTheranostics; QED Therapeutics
Stock and Other Ownership Interests - bioTheranostics; QED Therapeutics
 
Gary Li
Employment - QED Therapeutics
 
Carl L. Dambkowski
Employment - QED Therapeutics
 
Susan Moran
Employment - QED Therapeutics
 
Yining Ye
Employment - QED Therapeutics
 
Siamak Daneshmand
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation